Isopropyl Alcohol

Isopropyl Alcohol

SCHEMBL2167550

CC(C)O.CO.ClC(Cl)Cl.O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Isopropyl Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
TSHR P16473 3/20 0.42
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isopropyl Alcohol SCHEMBL4337774 0.95 ALDH1A1 (0.60) ALDH1A1LMNATSHRTDP1
Isopropyl Alcohol SCHEMBL6554536 0.95
Isopropyl Alcohol SCHEMBL5858313 0.91 ALDH1A1 (0.55) ALDH1A1LMNATSHRTDP1
Isopropyl Alcohol SCHEMBL27497569 0.91 ALDH1A1 (0.67) ALDH1A1LMNATSHRTDP1
Isopropyl Alcohol SCHEMBL5999087 0.91 ALDH1A1 (0.67) ALDH1A1LMNATSHRTDP1
Isopropyl Alcohol SCHEMBL7671116 0.91 ALDH1A1 (0.67) ALDH1A1LMNATSHRTDP1
Isopropyl Alcohol SCHEMBL52447 0.91
Isopropyl Alcohol SCHEMBL1150321 0.86
Chloroform SCHEMBL9617984 0.85 LMNA (0.50) ALDH1A1LMNATSHRTDP1
Chloroform SCHEMBL25447 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103044424-B A kind of method of matrine in enriching and purifying kuh-seng Daxing'an Mountainrange Lin Gebei psychrophile Science and Technology Co., Ltd. (CN) 2015-12-02 CN claimed
CN-103044424-B A kind of method of matrine in enriching and purifying kuh-seng Daxing'an Mountainrange Lin Gebei psychrophile Science and Technology Co., Ltd. (CN) 2015-12-02 CN disclosed
CN-102060677-B Method for enriching and purifying eugenol in Chinese pink herb DAXINGANLING GADOL SPORTS INGREDIENT CO LTD 2013-06-05 CN disclosed
US-8324177-B2 Triterpene compositions and methods for use thereof RESEARCH DEVELOPMENT FOUNDATION (US) 2012-12-04 US disclosed
US-20110294752-A1 TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2011-12-01 US disclosed
EP-1079824-B1 TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF RES DEV FOUNDATION (US) 2011-08-31 EP disclosed
US-7985435-B2 Triterpene compositions and methods for use thereof RESEARCH DEVELOPMENT FOUNDATION (US) 2011-07-26 US disclosed
US-20100189824-A1 TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF ARNTZEN CHARLES J 2010-07-29 US disclosed
EP-1355642-A4 INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS RES DEV FOUNDATION (US) 2007-04-04 EP disclosed
US-20060148732-A1 Inhibition of NF-kappaB by triterpene compositions RESEARCH DEVELOPMENT FOUNDATION 2006-07-06 US disclosed
US-6962720-B2 Triterpene compositions and methods for use thereof RESEARCH DEVELOPMENT FOUNDATION (US) 2005-11-08 US disclosed
US-6746696-B2 ANTITUMOR AGENTS; APOPTOSIS RESEARCH DEVELOPMENT FOUNDATION 2004-06-08 US disclosed
US-6689398-B2 CONTROLLING APOPTOSIS; ANTITUMOR AGENT; GLYCYRRHETINIC ACID MIXTURES RESEARCH DEVELOPMENT FOUNDATION 2004-02-10 US disclosed
EP-1355642-A2 INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS RESEARCH DEVELOPMENT FOUNDATION (US) 2003-10-29 EP disclosed
US-20030054052-A1 Triterpene compositions and methods for use thereof RESEARCH DEVELOPMENT FOUNDATION 2003-03-20 US disclosed
US-20030039705-A1 Triterpene compositions and methods for use thereof RESEARCH DEVELOPMENT FOUNDATION 2003-02-27 US disclosed
US-20030031738-A1 Triterpene compositions and methods for use thereof RESEARCH DEVELOPMENT FOUNDATION (US) 2003-02-13 US disclosed
US-6444233-B1 ANTITUMOR AGENTS RESEARCH DEVELOPMENT FOUNDATION 2002-09-03 US disclosed
WO-2002055016-A2 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS RES DEV FOUNDATION (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294752-A1 TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF OSTC, ACACA, NFATC1 ALDH1A1 2759/4885LMNA 419/4885TSHR 3986/4885
US-20100189824-A1 TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF OSTC, ACACA, NFATC1 ALDH1A1 2759/4885LMNA 419/4885TSHR 3986/4885
US-20030031738-A1 Triterpene compositions and methods for use thereof OSTC, ACACA, NFATC1 ALDH1A1 2759/4885LMNA 419/4885TSHR 3986/4885
US-20030039705-A1 Triterpene compositions and methods for use thereof BAX, CASP3, ACACA ALDH1A1 2361/4885LMNA 213/4885TSHR 3311/4885
US-20060148732-A1 Inhibition of NF-kappaB by triterpene compositions NFKBIA, NFKB2, RELA ALDH1A1 1797/4885LMNA 419/4885TSHR 4781/4885
US-20030054052-A1 Triterpene compositions and methods for use thereof OSTC, ACACA, NFATC1 ALDH1A1 2759/4885LMNA 419/4885TSHR 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.